A phase 1 randomized, double-blind, placebo-controlled, multiple ascending dose food and effect study
Latest Information Update: 25 Aug 2021
At a glance
- Drugs Deupirfenidone (Primary)
- Indications COVID-19 respiratory infection; Idiopathic pulmonary fibrosis; Lymphoedema
- Focus Pharmacokinetics
- Sponsors PureTech Health
- 25 Aug 2021 New trial record
- 24 Aug 2021 According to a PureTech Health media release, results from this trial is anticipated in the fourth quarter of 2021.
- 23 Aug 2021 Results published in the Media Release